Additional file 1 of Mendelian randomization and colocalization analysis reveal novel drug targets for myasthenia gravis

Supplementary Material 1: Table S1. Significant results of eQTL MR analysis. Table S2. Genetic information of SNPs associated with druggable genes. Table S3. Results of MR-Egger and MR-PRESSO analysis for pleiotropy test. Table S4. Results of Q and I2 analysis for heterogeneity test. Table S5. Results of F statistics and Steiger filtering analysis. Table S6. Results of colocalization analysis. Table S7. Results of pQTL MR analysis. Table S8. Characteristics of MG patients and healthy controls. Table S9. Clinical trial information of promising drug targets. Table S10. 821 phenotypes included for Phenome-wide MR (Phe-MR) analysis. Table S11. Results of Phe-MR analysis.

补充材料1：表S1。表达数量性状位点孟德尔随机化（eQTL MR）分析的显著结果。表S2。与可药用基因相关的单核苷酸多态性（Single Nucleotide Polymorphisms, SNPs）的遗传信息。表S3。用于多效性检验的MR-Egger与MR-PRESSO分析结果。表S4。用于异质性检验的Q值与I²值分析结果。表S5。F统计量与Steiger过滤分析结果。表S6。共定位分析结果。表S7。蛋白质数量性状位点孟德尔随机化（pQTL MR）分析结果。表S8。MG（重症肌无力，Myasthenia Gravis）患者与健康对照者的基线特征。表S9。潜在药物靶点的临床试验信息。表S10。全表型组孟德尔随机化（Phenome-wide MR, Phe-MR）分析所纳入的821项表型。表S11。全表型组孟德尔随机化（Phe-MR）分析结果。